1Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

1RareCyte, Inc., Seattle, WA.

Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Clin Cancer Res (2024) 30 (21_Supplement): B057.

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. This work is licensed under a Creative Commons Attribution 4.0 International ...

Jamie E. Medina; Akshaya V. Annapragada; Pien Lof; Sarah Short; Adrianna L. Bartolomucci; Dimitrios Mathios; Shashikant Koul; Noushin Niknafs; Michaël Noë ...

Autolus Therapeutics’ chimeric antigen receptor (CAR) T-cell therapy obecabtagene autoleucel (Aucatzyl) received FDA approval for adults with B-cell precursor acute lymphoblastic leukemia (ALL). The ...

A new targeted therapy aimed specifically at FGFR3, TYRA-300, is showing preliminary promise in patients with advanced FGFR3-altered bladder cancer. Partial responses have been seen in an ongoing ...

1Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, New York.